The recall affects countries in Europe, Asia, and North and South America, including Australia, Denmark and Japan. It impacts about 81,000 EpiPens. And patients can request a replacement for no cost.

The recall was a response to two cases of defective products that didn’t administer the proper reaction.

Though life threatening, both people received treatment at nearby hospitals. The company released a statement explaining that the number of reported failures is actually small. But since they’ve become aware that there could be defective parts, they feel the need to rectify the situation.

Anyone affected by the recall is instructed to go to Mylan’s website to get more information about replacing EpiPens. Given the volume of recalls, Mylan asks patients to hang on to theirs just to be safe.